Aura Biosciences, Inc. (NASDAQ:AURA) Given Consensus Rating of “Buy” by Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA) has received an average recommendation of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $22.75.

Several analysts have recently commented on the company. JMP Securities set a $19.00 price objective on Aura Biosciences in a research note on Wednesday, March 26th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Citigroup restated an “outperform” rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, HC Wainwright set a $25.00 target price on shares of Aura Biosciences in a report on Tuesday, March 25th.

Insider Buying and Selling at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 23,045 shares of company stock worth $177,242 in the last quarter. 5.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds have recently modified their holdings of AURA. Charles Schwab Investment Management Inc. increased its position in Aura Biosciences by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock worth $1,233,000 after buying an additional 3,612 shares during the last quarter. State Street Corp raised its position in shares of Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after purchasing an additional 26,841 shares during the period. Wellington Management Group LLP purchased a new stake in shares of Aura Biosciences during the 3rd quarter valued at approximately $1,037,000. Barclays PLC boosted its holdings in Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after buying an additional 43,897 shares during the period. Finally, Geode Capital Management LLC grew its stake in Aura Biosciences by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock valued at $8,990,000 after buying an additional 39,379 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Trading Down 7.3 %

Shares of AURA stock opened at $4.97 on Friday. Aura Biosciences has a 12 month low of $4.84 and a 12 month high of $12.38. The firm has a market capitalization of $249.62 million, a PE ratio of -2.87 and a beta of 0.43. The firm has a fifty day simple moving average of $7.01 and a two-hundred day simple moving average of $8.30.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.09). On average, equities analysts predict that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.